Eli Lilly and (LLY) Rating Reiterated by HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Eli Lilly and (NYSE:LLY) in a report published on Wednesday morning.

A number of other equities research analysts also recently issued reports on the stock. Argus raised shares of Eli Lilly and from a hold rating to a buy rating and increased their price target for the stock from $85.52 to $115.00 in a report on Friday, January 5th. Jefferies Group set a $100.00 price target on shares of Eli Lilly and and gave the stock a buy rating in a report on Tuesday, January 16th. Goldman Sachs downgraded shares of Eli Lilly and from a buy rating to a neutral rating and increased their price target for the stock from $86.98 to $95.00 in a report on Tuesday, January 16th. Credit Suisse Group downgraded shares of Eli Lilly and from a neutral rating to an underperform rating and set a $82.00 price target on the stock. in a report on Monday, January 22nd. Finally, JPMorgan Chase set a $105.00 price target on shares of Eli Lilly and and gave the stock a buy rating in a report on Monday, February 26th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of $93.16.

Shares of Eli Lilly and stock opened at $79.06 on Wednesday. Eli Lilly and has a 12-month low of $73.69 and a 12-month high of $89.09. The stock has a market capitalization of $87,373.93, a PE ratio of 18.47, a PEG ratio of 1.46 and a beta of 0.26. The company has a current ratio of 1.32, a quick ratio of 1.01 and a debt-to-equity ratio of 0.85.



Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 33.01%. The firm had revenue of $6.16 billion for the quarter, compared to the consensus estimate of $5.93 billion. During the same period in the prior year, the firm posted $0.95 earnings per share. The company’s revenue for the quarter was up 7.0% on a year-over-year basis. analysts anticipate that Eli Lilly and will post 4.87 earnings per share for the current year.

In other Eli Lilly and news, SVP Susan Mahony sold 22,544 shares of the stock in a transaction that occurred on Monday, April 16th. The shares were sold at an average price of $80.09, for a total transaction of $1,805,548.96. Following the transaction, the senior vice president now directly owns 45,652 shares in the company, valued at $3,656,268.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Jeffrey N. Simmons sold 9,625 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $81.12, for a total transaction of $780,780.00. Following the transaction, the senior vice president now owns 152,120 shares in the company, valued at $12,339,974.40. The disclosure for this sale can be found here. Insiders sold 42,970 shares of company stock worth $3,444,557 over the last ninety days. 0.11% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of LLY. Bank of Montreal Can grew its position in Eli Lilly and by 85.4% during the fourth quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock valued at $391,156,000 after acquiring an additional 2,133,606 shares during the last quarter. Investec Asset Management LTD bought a new position in Eli Lilly and during the fourth quarter valued at approximately $163,570,000. Janus Henderson Group PLC grew its position in Eli Lilly and by 16.1% during the third quarter. Janus Henderson Group PLC now owns 10,857,193 shares of the company’s stock valued at $928,719,000 after acquiring an additional 1,503,918 shares during the last quarter. Schroder Investment Management Group grew its position in Eli Lilly and by 81.3% during the fourth quarter. Schroder Investment Management Group now owns 2,300,675 shares of the company’s stock valued at $194,315,000 after acquiring an additional 1,031,859 shares during the last quarter. Finally, Amundi Pioneer Asset Management Inc. grew its position in Eli Lilly and by 110.9% during the fourth quarter. Amundi Pioneer Asset Management Inc. now owns 1,832,626 shares of the company’s stock valued at $154,783,000 after acquiring an additional 963,776 shares during the last quarter. Institutional investors and hedge funds own 77.66% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Eli Lilly and (LLY) Rating Reiterated by HC Wainwright” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://stocknewstimes.com/2018/04/22/eli-lilly-and-lly-rating-reiterated-by-hc-wainwright.html.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply